



Brussels, **XXX**  
SANTE/10220/2022 ANNEX feedback  
(POOL/E5/2022/10220/10220-EN  
ANNEX feedback.docx)  
[...] (2022) **XXX** draft

ANNEX

**ANNEX**

**to the**

**COMMISSION IMPLEMENTING REGULATION (EU) .../...**

**designating antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans, in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council**

## ANNEX

### Antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans

- (1) Antibiotics
  - (a) Carboxypenicillins
  - (b) Ureidopenicillins
  - (c) Ceftobiprole
  - (d) Ceftaroline
  - (e) Combinations of cephalosporins with beta-lactamase inhibitors
  - (f) Siderophore cephalosporins
  - (g) Carbapenems
  - (h) Penems
  - (i) Monobactams
  - (j) Phosphonic acid derivatives
  - (k) Glycopeptides
  - (l) Lipopeptides
  - (m) Oxazolidinones
  - (n) Macrocycles
  - (o) Plazomicin
  - (p) Glycylcyclines
  - (q) Eravacycline
  - (r) Omadacycline
- (2) Antivirals
  - (a) Amantadine
  - (b) Baloxavir marboxil
  - (c) Celgosivir
  - (d) Favipiravir
  - (e) Galidesivir
  - (f) Lactimidomycin
  - (g) Laninamivir
  - (h) Methisazone/metisazone
  - (i) Molnupiravir
  - (j) Nitazoxanide
  - (k) Oseltamivir
  - (l) Peramivir
  - (m) Ribavirin

- (n) Rimantadine
  - (o) Tizoxanide
  - (p) Triazavirin
  - (q) Umifenovir
  - (r) Zanamivir
- (3) Antiprotozoals
- (a) Nitazoxanide